Apalutamide (Erleada®) is indicated for the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/01/2019|
|Rapid review completed||27/02/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide in combination with ADT compared with the current standard of care.|